Related Experiment Videos
[Protective activity of a bacterial plasmid, bearing the gene for the tick-borne encephalitis virus NS1 nonstructural
Abstract:
Three intramuscular injections (50 micrograms each) with bacterial plasmid pMV45 carrying nonstructural gene of NS1 protein of tick-borne encephalitis (TBE) virus protected 88% Balb/c mice from lethal challenge with the virus. Antibodies to NS1 nonstructural protein were detected in the sera of vaccinated mice after the challenge. Absence of antibodies to E structural protein indicated absence of manifest infectious process in mice vaccinated with plasmid and challenged with a lethal dose of TBE virus.
Insights
Tick-borne encephalitis (TBE) virus vaccination using a plasmid encoding the NS1 protein protected mice from lethal infection. This TBE vaccine induced antibodies against NS1, indicating a potential new strategy for TBE prevention.
Area of Science:
- Virology
- Immunology
- Molecular Biology
Background:
- Tick-borne encephalitis (TBE) is a significant viral zoonosis transmitted by ticks.
- Current TBE vaccines primarily target the E structural protein.
- Developing alternative TBE vaccine strategies is crucial for disease control.
Purpose of the Study:
- To evaluate the efficacy of a DNA vaccine encoding the NS1 nonstructural protein of TBE virus.
- To assess the immune response generated by the NS1-based TBE vaccine in a mouse model.
Main Methods:
- Balb/c mice were immunized with three intramuscular injections of bacterial plasmid pMV45 (50 micrograms each) carrying the NS1 gene.
- Mice were subsequently challenged with a lethal dose of TBE virus.
- Antibody responses against NS1 and E proteins were analyzed post-challenge.
Main Results:
- The NS1 DNA vaccine conferred 88% protection against lethal TBE virus challenge.
- Humoral immunity against the NS1 protein was detected in vaccinated and challenged mice.
- Absence of antibodies to the E structural protein suggested a lack of manifest infection in protected mice.
Conclusions:
- The NS1 nonstructural protein of TBE virus is a viable target for vaccine development.
- A plasmid-based vaccine encoding NS1 demonstrates significant protective efficacy against TBE virus.
- This study highlights a novel approach for TBE vaccine design, potentially offering an alternative to existing E protein-based vaccines.